Addex Therapeutics

Addex Therapeutics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Addex Therapeutics (ADXN) as of Oct 18, 2026 is -8.19 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.30 M USD — a change of 148.26% (lower).

EBITDA

-8.19 MUSD

YoY

148.26%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Addex Therapeutics is 2025 -8.19 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Addex Therapeutics was 2024 -3.30 M USD. It decreases by 148.26% lower compared to the previous year.

The Addex Therapeutics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.71 M USD
Jan 1, 2019
-17.55 M USD
Jan 1, 2020
-15.36 M USD
Jan 1, 2021
-18.57 M USD
Jan 1, 2022
-12.91 M USD
Jan 1, 2023
-2.69 M USD
Jan 1, 2024
-3.30 M USD
Jan 1, 2025
-8.19 M USD
The Addex Therapeutics EBITDA history
YEAREBITDAYoY
-8.19 MUSD+148.26%
-3.30 MUSD+22.84%
-2.69 MUSD-79.19%
-12.91 MUSD-30.50%
-18.57 MUSD+20.91%
-15.36 MUSD-12.47%
-17.55 MUSD+928.49%
-1.71 MUSD-55.96%
-3.87 MUSD+2.98%
-3.76 MUSD-18.79%
-4.63 MUSD+115.29%
-2.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Addex Therapeutics Stock analysis

What does Addex Therapeutics do? Addex Therapeutics Ltd, based in Geneva, Switzerland, discovers and develops small-molecule pharmaceuticals targeting neurological disorders. The company focuses on G-protein coupled receptors and enzymes, with lead programs including Dipraglurant in Phase 1 for post-stroke/TBI recovery and Parkinson's disease, and ADX71149 in Phase 1 for undisclosed indications. It collaborates with Janssen Pharmaceuticals and Indivior PLC for GABAB PAM compounds addressing pain, anxiety, addiction, and other central nervous system conditions. Addex Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Addex Therapeutics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Addex Therapeutics is -8.19 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Addex Therapeutics changed from -3.30 M USD to -8.19 M USD, representing a 148.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Addex Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Addex Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Addex Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Addex Therapeutics